Envafolimab combined with capecitabine in TERT-mutant advanced biliary tract cancer:a case report
WANG Kai-yu
GUO Tian-yu
ZHANG Lei
ZHAO Hao-yu
WEI Ze-yuan
LIU Ye-fu
MA Zuo-hong
Abstract：The prognosis of patients with advanced cholangiocarcinoma(CCA)is exceedingly poor,and the efficacy of conventional chemotherapy remains limited.Therefore,there is an urgent need to explore new therapeutic strategies.Envafolimab recognized as the world's first subcutaneously administered programmed cell death ligand 1(PD-L1)inhibitor,has shown promising antitumor activity and safety in the treatment of various solid tumors.This article reports a case of advanced biliary tract cancer with telomerase reverse transcriptase(TERT)mutation and multiple intrahepatic metastases,which achieved significant clinical benefit following treatment with envafolimab combined with capecitabine.Through this case analysis,we aim to provide further reference for clinical practice.
Keywords：advanced cholangiocarcinomaenvafolimabintrahepatic metastasistelomerase reverse transcriptasemutationcapecitabine
Publication Date：2025-07-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 1402-1405 )